APA (7th ed.) Citation

W, F., J, C., S, A., M, K., F, T., V, S., . . . M, H. (2020). A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. British journal of haematology, 190(3), e169. https://doi.org/10.1111/bjh.16804

Chicago Style (17th ed.) Citation

W, Fiedler, et al. "A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients with Relapsed/refractory Acute Myeloid Leukaemia." British Journal of Haematology 190, no. 3 (2020): e169. https://doi.org/10.1111/bjh.16804.

MLA (9th ed.) Citation

W, Fiedler, et al. "A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients with Relapsed/refractory Acute Myeloid Leukaemia." British Journal of Haematology, vol. 190, no. 3, 2020, p. e169, https://doi.org/10.1111/bjh.16804.